title: Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study.
abstract: OBJECTIVE
  To assess therapeutic persistence and its relationship with concomitant medication in patients treated with fesoterodine versus tolterodine and solifenacin for overactive bladder (OAB) in standard clinical practice conditions.
  
  
  METHODS
  An observational, multicentre retrospective study was performed based on medical registries of patients followed-up in primary care (PC). Three study groups were analysed. Persistence was defined as the time (in months) without withdrawing from the initial therapy or without changing to another medication for at least 30 days after the initial prescription. The concomitant medications were antidepressants, anxiolytic/hypnotic agents, antibiotics, antiseptic agents, laxatives and skin products. We employed the SPSSWIN program version 17 (statistical significance, P<.05).
  
  
  RESULTS
  We selected 3094 patients for the study. The median age was 54.0 years and 62.2% were women. The patients treated with fesoterodine shown greater treatment persistence (12 months) when compared with those who took solifenacin and tolterodine (40.2% vs. 34.7% and 33.6%, respectively; P=.008). They also showed a lower use of concomitant medication (1.1 vs. 1.2 and 1.2 drugs, respectively; percentages: 61.6% vs. 67.1% and 70.1%, respectively; P<.03).
  
  
  CONCLUSIONS
  The patients undergoing OAB treatment with fesoterodine, when compared with those taking solifenacin and tolterodine, were associated with greater treatment persistence and a reduced use of concomitant medication.
authors.affiliation: Dirección de Planificación, Badalona Serveis Assistencials S.A., Badalona, Barcelona, España. Electronic address: asicras@bsa.cat.
authors.forename: A
authors.initials: A
authors.lastname: Sicras-Mainar
authors.affiliation: Documentación Médica, Hospital Germans Trias i Pujol, Badalona, Barcelona, España.
authors.forename: R
authors.initials: R
authors.lastname: Navarro-Artieda
authors.affiliation: Dirección de Atención Primaria, ib-Salut , Mallorca, España.
authors.forename: A
authors.initials: A
authors.lastname: Ruiz-Torrejón
authors.affiliation: GRECS, Universitat de Girona, Girona, España.
authors.forename: M
authors.initials: M
authors.lastname: Sáez-Zafra
authors.affiliation: Unitat de Recerca, IAS, Girona, España.
authors.forename: G
authors.initials: G
authors.lastname: Coll-de Tuero
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011320:Primary Health Care; D012189:Retrospective Studies; D000069464:Solifenacin Succinate / Q000627:therapeutic use*; D000068737:Tolterodine Tartrate / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D016903:Drug Monitoring
chemical_list: D001559:Benzhydryl Compounds; D018727:Muscarinic Antagonists; D000068737:Tolterodine Tartrate; C526675:fesoterodine; D000069464:Solifenacin Succinate
keywords: Antimuscarinic agents; Antimuscarínicos; Concomitant medication; Medicación concomitante; Overactive bladder; Persistence; Persistencia; Vejiga hiperactiva